SUNPHARMA — Sun Pharmaceutical Industries Income Statement

0.000.00%

Last trade - 00:00

HealthcareConservativeLarge CapHigh Flyer

Annual income statement for Sun Pharmaceutical Industries, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IAS	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	386,545	438,857	484,969	525,784	584,620
Cost of Revenue
Gross Profit	262,441	311,132	356,664	396,305	444,752
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	350,768	347,933	384,799	406,745	461,696
Operating Profit	35,777	90,924	100,169	119,039	122,924
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	44,813	94,084	110,879	137,521	151,189
Provision for Income Taxes
Net Income After Taxes	34,058	85,608	96,484	109,801	111,791
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	32,727	84,736	95,764	109,290	114,794
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	32,727	84,736	95,764	109,290	114,794
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	28	36	41.7	47.9	50.3
Dividends per Share